Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

BACKGROUND: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Commun (Lond)
Päätekijät: Kim, Ji-Yeon, Park, Seri, Im, Seock-Ah, Kim, Sung-Bae, Sohn, Joohyuk, Lee, Keun Seok, Chae, Yee Soo, Lee, Ki Hyeong, Kim, Jee Hyun, Im, Young-Hyuck, Kim, Tae-Yong, Lee, Kyung-Hun, Ahn, Jin-Hee, Kim, Gun Min, Park, In Hae, Lee, Soo Jung, Han, Hye Sook, Kim, Se Hyun, Jung, Kyung Hae, Park, Yeon Hee
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540535/
https://ncbi.nlm.nih.gov/pubmed/31138332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0375-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia